Day: August 31, 2023

GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023. Recent Business UpdatesTherapy Selection and Minimal Residual Disease (MRD)Presented study results on extensive-stage small-cell lung cancer and ovarian cancer at the ASCO in June 2023. “A Multicenter Phase I/II trial of Induction Chemotherapy Followed by Camrelizumab, Apatinib plus Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer” and “DNA methylation patterns between tissue and blood samples in ovarian cancers”. Precision oncology diagnostics product supports advancement...

Read the full half-year 2023 results press release here GROUP NET SALES UP 5.9% BACKLOG CONVERSION TO SIGNIFICANTLY ACCELERATE IN H2 CONTINUED INVESTMENT TO PREPARE FOR GROWTH; GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 31 August 2023 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2023.(EUR 000) H1 2023 H1 2022 Variance Variance %Total Net Sales 169 418 160 032 9 386 5.9%  Proton Therapy 95 082 101 338 -6 256 -6.2%  Other Accelerators 41 354 31 798 9 556 30.1%  Dosimetry 32 982 26 896 6 086 22.6%REBITDA -13 859 14 065 -27 924 -198.5%    % of Sales -8.2% 8.8%    REBIT -20 296 4 564 -24 860 -544.7%    % of Sales -12.0% 2.9%    Profit Before Tax -22 656 297 -22 953 -7728.3%    % of Sales -13.4% 0.2%    NET...

Platform growth and integrations leading to increased revenue and improved margins Highlights of Q2 2023Increased earnings driven by revenue growth and ongoing cost savings Net revenue of approximately € 122 million for Q2 2023, up from € 104 million in Q2 2022. Adjusted EBITDA of almost € 19 million, up by approximately 58% compared to Q2 2022. Upgraded expected annualized cost savings to at least € 20 million from at least € 15 million, excluding any effects from foreign exchange.  The expected savings are compared to the January 2023 baseline. Total operating expenses Q2 2023 of € 38.1 million (including restructuring costs) only € 1.9 million higher than Q2 2022 notwithstanding 8 acquisitions in H2 2022.  Sale of social card games portfolio completed 28 August 2023 for an initial cash consideration of € 81.3 million, subject to customary...

+14% year-on-year revenue growth in Core markets, driven by continued outstanding performance at mobile.de Total consolidated revenues at €465m, up +12%1 yoy Total consolidated EBITDA of €177m and reported margin of 38.0% 2023 outlook improved and long term ambition confirmedOslo, 31 August 2023 – Adevinta ASA (ADE) (“Adevinta” or “the Company”) reported another set of strong results in the second quarter of 2023, with a 14% year-on-year revenue growth for its Core Markets. This can be attributed to outstanding performance of mobile.de, supported by continued strong results in other segments.Online classifieds revenues improved by 17%, once again supported by continued strong double-digit revenue growth in Mobility, mostly driven by mobile.de, which benefited from the successful new price increase implemented in April...

Dear shareholder, Dear Madam, Dear Sir,In spite of a more challenging economic environment, the contribution of the core segments of 149.6 million euros is down only 4% from H1 2022. Delen Private Bank and Bank Van Breda have further reinforced their leading market position and posted stellar performances. As expected, capital gains contributed less than in the record year 2022. The capital gain on the exit of Telemond in H1 2023 illustrates the potential of AvH’s diversified portfolio. AvH’s net financial position grew further to 511 million euros at June 30, 2023. “The diversification of our portfolio has once again proven its relevance in an environment which remains challenging, with a result of our core segments very close to our strong H1 2022 results.  Our banks reported a strong performance on the back of continued...

Oslo (Norway), 31 August 2023 – PCI Biotech (OSE: PCIB), today announces its interim first half 2023 results. Please find enclosed the report and presentation. Highlights review fimaNAc – bioprocessingThe bioprocessing program for use of fimaNAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Continued focus on generating results that can trigger field testing with potential customers to get feedback and develop a competitive technology. fimaNAc – dermatologyFor dermatology the study to demonstrate topical fimaNAc-mediated nucleic acid delivery in a preclinical wound model is completed. The study demonstrated significant delivery in a simplified model, but these results were not translatable into the selected full-scale model when testing topical delivery of unprotected...

In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonology returning to positive growth year-over-year. Today, Ambu narrows its full-year 2022/23 organic revenue growth guidance to 6-8%, previously 5-8%, based on the company’s performance in Q3 and the first two months of Q4. On 10 July 2023, Ambu adjusted its financial guidance by upgrading its full-year EBIT margin before special items to 5-6%, previously 3-5%, driven by a better-than-expected gross margin, due to a strengthened product mix. In Q3, free cash flow ended at DKK 157m before acquisitions and is expected to reach an improvement of more than DKK 500m (previously DKK 350-450m) for the full-year 2022/23, compared to 2021/22. “I am pleased...